Please login to the form below

Not currently logged in
Email:
Password:

Vertex Pharma

This page shows the latest Vertex Pharma news and features for those working in and with pharma, biotech and healthcare.

Vertex to lead development of CRISPR Therapeutics-partnered gene therapy

Vertex to lead development of CRISPR Therapeutics-partnered gene therapy

as we bring forward our broad gene and cell-based therapeutics portfolio,” said Jeffrey Leiden, executive chairman of Vertex. ... Along with Vertex/CRISPR Therapeutics, bluebird bio is also seeking to bring its gene therapy LentiGlobin for SCD (bb1111)

Latest news

More from news
Approximately 6 fully matching, plus 50 partially matching documents found.

Latest Intelligence

  • Health trust in a COVID-19 world – a unique opportunity for pharma Health trust in a COVID-19 world – a unique opportunity for pharma

    There were also some high-profile reimbursement stand-offs between pharma and the NHS (eg, Vertex/Orkambi). ... to the pharma industry, which is seen as being responsible for the high price of medicines).

  • The Cystic Fibrosis Buyers’ Club The Cystic Fibrosis Buyers’ Club

    This includes overriding pharma patents – something the group is advocating in relation to three drugs – Vertex’s cystic fibrosis treatment Orkambi, Pfizer’s breast cancer treatment Ibrance and Roche’s breast ... Meticulous preparations. The

  • Vertex: a vision of treating all CF patients worldwide draws closer Vertex: a vision of treating all CF patients worldwide draws closer

    Its high prices are controversial, but Vertex also embodies the best of biopharma drug development. ... The failure of Proteostasis has led analysts to upgrade forecasts for Vertex’s own franchise.

  • The Orkambi blame game The Orkambi blame game

    The deadlock between pharma company Vertex and NHS England over cystic fibrosis drug Orkambi was played out in a parliamentary hearing in London on 7 March, when the company’s CEO ... NHS England accusing Vertex of being an“extreme outlier” and

  • 2019: CRISPR and therapeutic gene editing comes of age 2019: CRISPR and therapeutic gene editing comes of age

    The green light came after a delay of around a year caused by manufacturing issues, which allowed another candidate from CRISPR Therapeutics and Vertex Pharma - CTX001 for the rare blood disease

More from intelligence
Approximately 1 fully matching, plus 7 partially matching documents found.

Latest appointments

  • Vertex poaches new finance chief from Ironwood Pharmaceuticals Vertex poaches new finance chief from Ironwood Pharmaceuticals

    Boston-based biotech company appoints Tom Graney. Vertex lured Tom Graney away from Ironwood Pharmaceuticals, appointing him as its new senior vice president and chief financial officer. ... Tom has the ideal blend of financial acumen, leadership skills,

  • BMS appoints three independent directors BMS appoints three independent directors

    Meanwhile, Matthew Emmens and Theodore Samuels also join the pharma firm's board of directors. ... Since beginning his pharmaceutical career 40 years ago, Emmens has served as president, chief executive officer and chairman of Vertex Pharma, chief

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Nucleus Global

Nucleus Global is the largest specialist medical communications network in the world. Globally, we have over 800 experts delivering world-class...

Latest intelligence

Human behaviour - Sept 21
All change – how untangling human behaviour can encourage better health
Driving better patient outcomes through clear, achievable practical steps that are underpinned by transparent evidence...
Health literacy in the time of COVID-19
In a time when much of the media’s focus is on the ongoing COVID-19 pandemic and the differences in vaccination rates between various regions, countries, and socioeconomic groups, improving health...
Rare thoughts & outcomes - navigating pathways to better outcomes in rare
...